Search Share Prices
Abzena moves into new Cambridge HQ
AIM-listed life sciences group Abzena said on Friday that it had moved into new headquarters on the Babraham Research Campus in Cambridge.
Abzena is consolidating all its UK operations including the head office functions, biology and chemistry research services groups from its two current buildings on the campus into this new facility during January 2018.
The new building has been purpose-built to accommodate Abzena's needs and enables all the group's UK-based science teams to work together in a single, state-of-the-art facility, the company said in an update.
The Group has also entered into an agreement with Babraham Bioscience Technologies (BBT) to run and develop the antibody discovery services formerly provided by BBT's Technology Development Laboratory.
In the US Abzena has negotiated and now concluded a lease for a 50,000 square feet facility at Lusk Boulevard, San Diego to consolidate the West Coast biomanufacturing operations into a single state of the art facility.
"Abzena's process and analytical development groups will relocate from the existing Torrey Pines laboratories in the second quarter of this year," the company said.
"Following further remodelling of the facility, enabled by substantial landlord-funded tenant improvements to create the biomanufacturing clean rooms to accommodate 500L and 2,000 litre bioreactors, the manufacturing group will relocate to the new facility. The facility is expected to be fully operational from early 2019."
"The group has entered into a preferred biomanufacturing equipment supply and services agreement, as announced by Sartorius Stedim Biotech SA on 4 January 2018, to supply the bioprocess reactor equipment, process analytic software and to provide support for the design of the new biomanufacturing facility in San Diego."
"The creation of the GMP conjugation suite at Abzena's Bristol, PA facility is continuing on track and is expected to be operational around the end of the first quarter of 2018."